An advisory panel for the US Food and Drug Administration has recommended Johnson & Johnson’s single-dosevaccine be given the green light by the FDA. The FDA Vaccines and Related Biological Products Advisory Committee unanimously voted Friday afternoon to approve the vaccine.
The next step will be emergency approval from the FDA itself.
In early February, a week after announcing that its single-dosewas 66% effective overall in preventing COVID-19 in a global clinical trial, Johnson & Johnson submitted an application .
It would be the third vaccine on the US market, following the FDA granting emergency use authorization for theand coronavirus vaccines in December, with vaccinations beginning just days later. Those vaccines are said to be 95% and 94% effective, respectively. Unlike the Pfizer and Moderna vaccines, .
Earlier this month, President Joe Biden announced that the US is buying enough doses ofin the country by the end of July — though this doesn’t mean everyone will be vaccinated by then.
“We’ve now purchased enough vaccine supply to vaccinate all Americans,” Biden said. Actually administering the vaccines to all Americansbecause vaccinations are managed at a state and local level.
Here’s, and here’s how to in your state.
Read More: https://www.cnet.com/health/fda-panel-gives-johnson-johnson-one-shot-covid-19-vaccine-green-light/